Comparative Pharmacology
Head-to-head clinical analysis: BUPIVACAINE LIPOSOME versus LIDOCAINE HYDROCHLORIDE W EPINEPHRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPIVACAINE LIPOSOME versus LIDOCAINE HYDROCHLORIDE W EPINEPHRINE.
BUPIVACAINE LIPOSOME vs LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine liposome is a long-acting local anesthetic that reversibly blocks nerve impulse propagation by inhibiting sodium ion influx through voltage-gated sodium channels in neuronal cell membranes. The liposomal formulation provides sustained release of bupivacaine, prolonging analgesic effect.
Lidocaine is a sodium channel blocker that inhibits voltage-gated sodium channels, preventing depolarization and conduction of nerve impulses. Epinephrine is an alpha- and beta-adrenergic agonist that causes vasoconstriction, reducing systemic absorption of lidocaine and prolonging local anesthetic effect.
Local infiltration: up to 266 mg (20 mL of 1.3% or 10 mL of 2.66%) single dose; interscalene brachial plexus block: up to 133 mg (10 mL of 1.3%) single dose; sciatic nerve block in the popliteal fossa: up to 133 mg (10 mL of 1.3%) single dose; adductor canal block: up to 133 mg (10 mL of 1.3%) single dose; max dose 266 mg per procedure.
Local anesthesia: 1-5 mL of 1% or 2% solution with epinephrine 1:100,000 or 1:200,000; maximum dose 7 mg/kg lidocaine (500 mg without epinephrine, 7 mg/kg with epinephrine) per procedure. Intravenous: 1-1.5 mg/kg bolus for ventricular arrhythmias, followed by continuous infusion 1-4 mg/min.
None Documented
None Documented
Terminal elimination half-life is approximately 12-24 hours (mean 18 hours) due to prolonged release from liposomal depot; significantly longer than conventional bupivacaine (2-4 hours), reflecting slow absorption rate-limited elimination.
Terminal half-life 1.5-2 hours (single dose), prolonged to 2-3 hours with continuous infusion; in heart failure or hepatic cirrhosis, half-life may exceed 5 hours.
Primarily hepatic metabolism to 3-hydroxybupivacaine and desbutylbupivacaine; renal excretion of metabolites accounts for ~95% of elimination, with <5% unchanged drug excreted in urine; biliary/fecal excretion minimal (<5%).
Renal: unchanged drug <10%, major metabolites (MEGX and GX) ~70% renal; biliary: <10% fecal; total clearance ~10-20 mL/min/kg. Renal impairment prolongs elimination of metabolites.
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)